Marina Biotech makes organisational changes
Creates the position of executive vice president of r&d
Richard Ho has joined the firm in the newly created position of executive vice president, Research and Development.
In addition, Philip Ranker has become interim chief financial officer, replacing Peter Garcia who has resigned from the role to pursue other opportunities.
Barry Polisky has moved from chief scientific officer to distinguished scientist and has become chairman of the firm's Scientific Advisory Panel and Michael Templin has been promoted to the newly created position of senior vice president and chief technology officer.
Finally, Alan Dunton has joined the firm as consulting chief medical officer.
Marina Biotech’s goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies.
You may also like
Regulatory
Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria
Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)
With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases